omniture
信达生物

Latest News

Innovent Announces NMPA Granted New Indication Approval for SULINNO® (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis

SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-11-23 18:34 5674

Innovation Drives Excellence, Innovent Successfully Held 2020 Virtual R&D Day

SAN FRANCISCO and SUZHOU, China, Nov. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-11-11 08:00 5207

Innovent Releases Phase 1a Results of CD47 Monoclonal Antibody (Letaplimab) in Monotherapy for Advanced Malignancies at SITC 2020

SAN FRANCISCO, U.S. and SUZHOU, China, Nov. 11, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Inn...

2020-11-11 08:00 4542

Innovent and Lilly Jointly Announce Results of Seven Clinical Studies of TYVYT® (sintilimab injection) to Be Presented at the ESMO ASIA Congress 2020

SAN FRANCISCO and SUZHOU, China, Nov. 5, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-11-05 08:00 3751

Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group

SAN FRANCISCO and SUZHOU, China, Oct. 15, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-10-15 08:00 10213

Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA® (Rituximab Injection) in China

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2020-10-09 19:14 8975

Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period

SAN FRANCISCO and SUZHOU, China, Oct. 7, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-10-07 08:00 12085

Innovent Biologics Announces to Host 2020 Virtual R&D Day on November 10th

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2020-09-28 12:13 3382

Innovent Announces NMPA Granted Marketing Approval for SULINNO® (Adalimumab Injection) in China

SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Inno...

2020-09-03 17:50 3274

Innovent Announces First Subject Dosed in the Phase 1 Clinical Trial of Anti-IL-23 Monoclonal Antibody

SAN FRANCISCO, and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2020-09-01 08:00 1556

Innovent Announces the Results of the Phase 1/2 Clinical Study of PCSK9 Antibody Tafolecimab at the European Society of Cardiology Annual Conference

SAN FRANCISCO and SUZHOU, China, Aug. 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2020-08-31 08:00 3958

Innovent Announces Financial Results for Six Months Ended June 30, 2020 and Corporate Progress

SAN FRANCISCO, U.S. and SUZHOU, China, Aug. 27, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (...

2020-08-27 09:37 8071

Innovent and Lilly Announce Expansion of TYVYT® (Sintilimab Injection) Licensing Agreement

SUZHOU, China and INDIANAPOLIS, Aug. 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-08-18 18:30 4418
12345